Loading...
XNAS
NSPR
Market cap77mUSD
Jun 02, Last price  
2.54USD
1D
-0.78%
1Q
-14.77%
Jan 2017
-100.00%
IPO
-100.00%
Name

InspireMD Inc

Chart & Performance

D1W1MN
No data to show
P/E
49.98
P/S
11.10
EPS
0.05
Div Yield, %
—
Shrs. gr., 5y
213.11%
Rev. gr., 5y
13.50%
Revenues
7m
+12.96%
006,004,0005,349,0004,873,0002,818,0002,310,0001,894,0002,761,0003,601,0003,721,0002,485,0004,495,0005,171,0006,205,0007,009,000
Net income
2m
P
-3,825-23,976-14,665,000-17,597,000-29,258,000-25,095,000-15,585,000-8,461,000-8,438,000-7,240,000-10,040,000-10,544,000-14,918,000-18,491,000-19,916,0001,557,000
CFO
-22m
L+33.54%
-825-18,981-6,003,000-8,580,000-10,300,000-19,362,000-11,596,000-7,495,000-8,131,000-7,606,000-9,810,000-9,081,000-13,210,000-15,542,000-16,376,000-21,868,000
Earnings
Aug 04, 2025

Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
URL
https://www.inspiremd.com/en/
IPO date
Apr 12, 2013
Employees
55
Domiciled in
IL
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
7,009
12.96%
6,205
20.00%
5,171
15.04%
Cost of revenue
40,512
27,348
23,884
Unusual Expense (Income)
NOPBT
(33,503)
(21,143)
(18,713)
NOPBT Margin
Operating Taxes
59
65
28
Tax Rate
NOPAT
(33,562)
(21,208)
(18,741)
Net income
1,557
-107.82%
(19,916)
7.71%
(18,491)
23.95%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,598
37,534
(140)
BB yield
-1.45%
-55.04%
2.07%
Debt
Debt current
557
419
Long-term debt
3,592
2,633
2,390
Deferred revenue
Other long-term liabilities
1,247
1,084
995
Net debt
(31,045)
(35,833)
(14,994)
Cash flow
Cash from operating activities
(21,868)
(16,376)
(15,542)
CAPEX
(1,402)
(381)
(473)
Cash from investing activities
12,641
(16,092)
8,441
Cash from financing activities
18,452
37,534
(140)
FCF
(35,760)
(7,980)
(32,789)
Balance
Cash
34,637
39,023
17,803
Long term investments
Excess cash
34,287
38,713
17,544
Stockholders' equity
(253,503)
(221,499)
(201,584)
Invested Capital
292,632
263,679
221,586
ROIC
ROCE
EV
Common stock shares outstanding
41,928
24,268
7,872
Price
2.63
-6.41%
2.81
226.93%
0.86
-71.54%
Market cap
110,272
61.70%
68,194
907.91%
6,766
-69.50%
EV
79,227
32,361
(8,228)
EBITDA
(33,223)
(20,911)
(18,525)
EV/EBITDA
0.44
Interest
28
Interest/NOPBT